122 related articles for article (PubMed ID: 29673963)
1. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2018 Dec; 48(3):399-405. PubMed ID: 29673963
[TBL] [Abstract][Full Text] [Related]
2. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.
Kang EH; Jin Y; Brill G; Lewey J; Patorno E; Desai RJ; Kim SC
J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367417
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Xie F; Yun H; Bernatsky S; Curtis JR
Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
[TBL] [Abstract][Full Text] [Related]
4. Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis.
Schäfer M; Meißner Y; Kekow J; Berger S; Remstedt S; Manger B; Listing J; Strangfeld A; Zink A
Rheumatology (Oxford); 2020 Aug; 59(8):1916-1926. PubMed ID: 31745566
[TBL] [Abstract][Full Text] [Related]
5. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
Simon TA; Suissa S; Skovron ML; Frisell T; Askling J; Michaud K; Pedro S; Strangfeld A; Meissner Y; Boers M; Hoffman V; Dominique A; Gomez A; Hochberg MC
Semin Arthritis Rheum; 2024 Feb; 64():152313. PubMed ID: 38044241
[TBL] [Abstract][Full Text] [Related]
6. Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
Simon TA; Dong L; Suissa S; Michaud K; Pedro S; Hochberg M; Boers M; Askling J; Frisell T; Strangfeld A; Meissner Y; Khaychuk V; Dominique A; Maldonado MA
Ann Rheum Dis; 2024 Jan; 83(2):177-183. PubMed ID: 37932010
[TBL] [Abstract][Full Text] [Related]
7. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
Simon TA; Suissa S; Boers M; Hochberg MC; Skovron ML; Askling J; Michaud K; Strangfeld A; Pedro S; Frisell T; Meissner Y; Dominique A; Gomez A
Semin Arthritis Rheum; 2024 Feb; 64():152240. PubMed ID: 37500379
[TBL] [Abstract][Full Text] [Related]
8. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort.
Meissner Y; Richter A; Manger B; Tony HP; Wilden E; Listing J; Zink A; Strangfeld A
Ann Rheum Dis; 2017 Sep; 76(9):1583-1590. PubMed ID: 28483768
[TBL] [Abstract][Full Text] [Related]
9. Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission.
Kedra J; Dieudé P; Giboin C; Marotte H; Salliot C; Schaeverbeke T; Perdriger A; Soubrier M; Morel J; Constantin A; Dernis E; Royant V; Salmon JH; Pham T; Gottenberg JE; Pertuiset E; Dougados M; Devauchelle-Pensec V; Gaudin P; Cormier G; Goupille P; Mariette X; Berenbaum F; Alcaix D; Rouidi SA; Berthelot JM; Monnier A; Piroth C; Lioté F; Goëb V; Gaujoux-Viala C; Chary-Valckenaere I; Hajage D; Tubach F; Fautrel B;
Arthritis Rheumatol; 2024 Apr; 76(4):541-552. PubMed ID: 37942714
[TBL] [Abstract][Full Text] [Related]
10. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Gautam N; Kim SC
Lancet Rheumatol; 2020 Feb; 2(2):e84-e98. PubMed ID: 38263664
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine use is associated with reduced mortality risk in older adults with rheumatoid arthritis.
Iyer P; Gao Y; Jalal D; Girotra S; Singh N; Vaughan-Sarrazin M
Clin Rheumatol; 2024 Jan; 43(1):87-94. PubMed ID: 37498463
[TBL] [Abstract][Full Text] [Related]
12. Using a modified Delphi process to establish clinical consensus for the diagnosis, risk assessment and abatacept treatment in patients with aggressive rheumatoid arthritis.
Caporali R; Carletto A; Conti F; D'Angelo S; Foti R; Gremese E; Govoni M; Iannone F; Pellerito R; Sinigaglia L
Clin Exp Rheumatol; 2017; 35(5):772-776. PubMed ID: 28281459
[TBL] [Abstract][Full Text] [Related]
13. Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
Pawar A; Desai RJ; He M; Bessette L; Kim SC
ACR Open Rheumatol; 2021 Aug; 3(8):531-539. PubMed ID: 34196497
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab-induced pulmonary fibrosis in a patient with rheumatoid arthritis.
Silva S; Amarasena R; Moorcroft J; Rajakulenthiran T; Singh R
Clin Med (Lond); 2020 Mar; 20(Suppl 2):s57. PubMed ID: 32409376
[No Abstract] [Full Text] [Related]
15. Abatacept-associated panniculitis in a patient with rheumatoid arthritis.
Nagatomi H; Yamashita D; Kitao R; Nishioka H
BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37380375
[No Abstract] [Full Text] [Related]
16. Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients.
Xie F; Yun H; Levitan EB; Muntner P; Curtis JR
Arthritis Care Res (Hoboken); 2019 Aug; 71(8):1004-1018. PubMed ID: 30175897
[TBL] [Abstract][Full Text] [Related]
17. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study.
Otsuka Y; Kiyohara C; Kashiwado Y; Sawabe T; Nagano S; Kimoto Y; Ayano M; Mitoma H; Akahoshi M; Arinobu Y; Niiro H; Akashi K; Horiuchi T
PLoS One; 2018; 13(4):e0196368. PubMed ID: 29694426
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients.
Mekinian A; Resche-Rigon M; Comarmond C; Soriano A; Constans J; Alric L; Jego P; Busato F; Cabon M; Dhote R; Estibaliz L; Koné-Paut I; Landron C; Lavigne C; Lioger B; Michaud M; Ruivard M; Sacre K; Gottenberg JE; Gaches F; Goulenok T; Salvarani C; Cacoub P; Fain O; Saadoun D;
J Autoimmun; 2018 Jul; 91():55-60. PubMed ID: 29678346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
